---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-25-000017"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:57:19.775589+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Evolus reports record Q4 2024 revenue $79.0M (+30% YoY); achieves full-year profitability ahead of expectations

## Summary
- Record Q4 revenue $79.0M (+30% YoY); full-year $266.3M (+32% YoY).
- GAAP op loss improved to $2.3M Q4; non-GAAP op income $6.7M Q4 and $0.3M full year (profitability ahead of schedule).
- Evolysse FDA approval Feb 2025; launch Q2 2025; expected 8-10% of 2025 revenue.
- 2025 revenue guidance $345-355M (30-33% growth); expects positive non-GAAP op income for full year.
- Added ~2,900 new accounts in 2024; total >15,300 accounts; over 50% US account penetration.

## SEC filing metadata
- accession: 0001570562-25-000017
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056225000017/0001570562-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056225000017/eols-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-25-000017
- JSON: https://secwatch.observer/filing/0001570562-25-000017.json
- Plain text: https://secwatch.observer/filing/0001570562-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.